OASIS: A Phase 2/3 Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Talactoferrin Alfa in Patients With Severe Sepsis

Trial Profile

OASIS: A Phase 2/3 Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Talactoferrin Alfa in Patients With Severe Sepsis

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 01 Sep 2015

At a glance

  • Drugs Talactoferrin alfa (Primary)
  • Indications Sepsis
  • Focus Therapeutic Use
  • Acronyms OASIS
  • Sponsors Agennix AG
  • Most Recent Events

    • 27 Aug 2014 Planned primary completion date changed to 1 Jan 2014.
    • 17 Apr 2014 New trial record
    • 02 Feb 2012
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top